Bionano Genomics, Inc. (BNGO) Financial Statements (2026 and earlier)

Company Profile

Business Address 9540 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9,47566,771113,186250,61238,44917,311
Cash and cash equivalent9,17317,9485,09124,57138,44917,311
Short-term investments30248,823108,095226,041  
Restricted cash and investments11,00035,117    
Receivables4,7749,6617,4965,3212,7756,334
Inventory, net of allowances, customer advances and progress billings13,27627,60229,76112,3873,3163,444
Inventory13,27627,60229,76112,3873,3163,444
Prepaid expense7631,1021,6321,7461,788712
Other current assets1,3189762,4122,348462457
Other undisclosed current assets(1,117)(1,111)2,811   
Total current assets:39,489140,118157,298272,41446,78928,258
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization3,2993,5033,7073,926  
Operating lease, right-of-use asset1,8045,6337,2226,691  
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization19,21923,34518,02910,3184,9101,950
Intangible asset, including goodwill, after accumulated amortization9,70533,974118,43283,0028,647 
Goodwill   77,28956,1607,173 
Intangible asset, excluding goodwill, after accumulated amortization9,70533,97441,14326,8421,475 
Restricted cash and investments 400400400   
Other noncurrent assets2,7547,4312,414749103 
Total noncurrent assets:37,18174,286150,204104,68613,6601,950
TOTAL ASSETS:76,670214,404307,502377,10060,45030,208
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,60318,47323,08619,3908,5285,925
Accounts payable6,96210,38412,5349,6962,9302,699
Accrued liabilities5,6418,08910,5529,6945,5993,225
Deferred revenue1,128783871684416357
Debt260272285299 20,085
Business combination, contingent consideration, liability   9,382   
Other undisclosed current liabilities23,35380,5002,2601,467  
Total current liabilities:37,344100,02835,88421,8408,94426,367
Noncurrent Liabilities
Long-term debt and lease obligation3,5393,5853,6198,93016,326 
Long-term debt, excluding current maturities     16,326 
Finance lease, liability3,5393,5853,6193,642  
Liabilities, other than long-term debt41214,63418,60114698227
Deferred revenue26715412714698183
Other liabilities      44
Operating lease, liability1453,5905,5045,288  
Business combination, contingent consideration, liability  10,89012,970   
Other undisclosed noncurrent liabilities    9,066  
Total noncurrent liabilities:3,95118,21922,22018,14216,423227
Total liabilities:41,295118,24758,10439,98225,36726,594
Equity
Equity, attributable to parent35,37596,157249,398337,11835,0823,614
Common stock 53029193
Additional paid in capital728,573677,337599,207553,747178,747106,188
Accumulated other comprehensive income (loss)2723(1,124)(539)  
Accumulated deficit(693,225)(581,208)(348,715)(216,119)(143,684)(102,577)
Total equity:35,37596,157249,398337,11835,0823,614
TOTAL LIABILITIES AND EQUITY:76,670214,404307,502377,10060,45030,208

Income Statement (P&L) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues30,77636,11627,80217,9818,50310,130
Cost of revenue
(Cost of Product and Service Sold)
(30,396)(26,550)(21,857)(14,107)(5,730)(6,768)
Gross profit:3809,5665,9453,8742,7733,361
Operating expenses(96,341)(224,811)(137,643)(80,975)(41,324)(29,236)
Other undisclosed operating loss (8,022)     
Operating loss:(103,983)(215,245)(131,698)(77,101)(38,551)(25,875)
Nonoperating income (expense)(8,001)(17,186)986(1,051)(2,526)(3,919)
Other nonoperating income (expense)(10,102)3,449(223)(59)(7)(299)
Interest and debt expense(271)(5,119)(298)(2,076)(2,519)(1,333)
Loss from continuing operations before equity method investments, income taxes:(112,255)(237,550)(131,010)(80,228)(43,596)(31,128)
Other undisclosed income from continuing operations before income taxes2715,1192982,0762,5191,333
Loss from continuing operations before income taxes:(111,984)(232,431)(130,712)(78,152)(41,077)(29,794)
Income tax expense (benefit)(33)(62)(1,884)5,717(29)(21)
Loss from continuing operations:(112,017)(232,493)(132,596)(72,435)(41,106)(29,815)
Loss before gain (loss) on sale of properties:(72,435)(41,106)(29,815)
Net loss available to common stockholders, diluted:(112,017)(232,493)(132,596)(72,435)(41,106)(29,815)

Comprehensive Income ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(112,017)(232,493)(132,596)(72,435)(41,106)(29,815)
Comprehensive loss:(112,017)(232,493)(132,596)(72,435)(41,106)(29,815)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent41,147(585)(539)  
Comprehensive loss, net of tax, attributable to parent:(112,013)(231,346)(133,181)(72,974)(41,106)(29,815)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: